SANTA CLARA, Calif., Aug. 5, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the second quarter ended June 30, 2024. In addition, the Company announced the purchase of an additional 101 bitcoins for an aggregate amount of $6.0 million. Since announcing the adoption of a bitcoin treasury strategy on May 28, 2024, the Company has purchased 929 bitcoins for a total of $63.0 million.
"We are pleased to report strong income from operations of $5.4 million in the second quarter," said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. "We remain laser focused on acquiring and holding bitcoin, while supporting and expanding our healthcare business."
"We are very encouraged by the strong positive reaction to our recent announcement of a bitcoin treasury strategy," said Eric Semler, chairman of Semler Scientific. "We continue to firmly believe that bitcoin is a compelling investment and plan on acquiring additional bitcoins with our cash from operations, as well as with cash generated from the sale of securities under our $150.0 million shelf registration statement, once effective."
FINANCIAL RESULTS
For the second quarter ended June 30, 2024, compared to the corresponding period of 2023, Semler Scientific reported:
Semler Scientific's three largest customers (including their affiliates) comprised 44%, 27% and 11% of second quarter 2024 revenues, respectively, and its two largest customers comprised 37% and 34% of second quarter 2023 revenues, respectively.
BITCOIN HOLDINGS
On May 28, 2024, Semler Scientific announced the initial purchase of 581 bitcoins for an aggregate amount of $40.0 million. On June 6, 2024, the Company announced the purchase of an additional 247 bitcoins for an aggregate amount of $17.0 million. On June 28, 2024, the Company purchased an additional 49 bitcoins for an aggregate cost of $3.0 million. As of June 30, 2024, the Company held 877 bitcoins with a fair value of $54.9 million, which reflects a cumulative reduction in fair value of $5.1 million.
Subsequently through August 5, 2024, the Company has purchased an additional 52 bitcoins for an aggregate cost of $3.0 million. Semler Scientific's total holdings as of August 5, 2024 are 929 bitcoins for an aggregate purchase amount of $63.0 million. All purchase amounts include fees and expenses.
Notice of Conference Call
Semler Scientific will host a conference call today at 4:30 p.m. ET. The call will address results of the second quarter ended June 30, 2024, as well as provide a business update on Semler Scientific's strategies for the near-term future. Questions can be submitted prior to the start of the call to This email address is being protected from spambots. You need JavaScript enabled to view it..
Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10190580/fcfdde76dc. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or who are unable to pre-register may dial in by calling:
Domestic callers: (833) 816‑1161
International callers: (412) 317‑0717
Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific's website at www.semlerscientific.com.
Semler Scientific, Inc. | ||||||||||||
Condensed Statements of Income | ||||||||||||
Unaudited | ||||||||||||
(In thousands of U.S. Dollars, except share and per share data) | ||||||||||||
For the three months ended June 30, | For the six months ended June 30, | |||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||
Revenues | $ | 14,465 | $ | 18,605 | $ | 30,368 | $ | 36,811 | ||||
Operating expenses: | ||||||||||||
Cost of revenues | 1,255 | 1,219 | 2,501 | 2,488 | ||||||||
Engineering and product development | 1,440 | 1,762 | 2,578 | 3,392 | ||||||||
Sales and marketing | 3,456 | 4,985 | 7,131 | 10,177 | ||||||||
General and administrative | 2,964 | 3,459 | 5,832 | 7,318 | ||||||||
Total operating expenses | 9,115 | 11,425 | 18,042 | 23,375 | ||||||||
Income from operations | 5,350 | 7,180 | 12,326 | 13,436 | ||||||||
Interest and dividend income | 714 | 597 | 1,534 | 1,080 | ||||||||
Change in fair value of notes held for investment | 128 | (111) | 128 | (217) | ||||||||
Change in fair value of digital assets | (5,055) | — | (5,055) | — | ||||||||
Other (expense) income, net | (4,213) | 486 | (3,393) | 863 | ||||||||
Pre-tax income | 1,137 | 7,666 | 8,933 | 14,299 | ||||||||
Income tax provision | 1,126 | 1,787 | 2,849 | 3,451 | ||||||||
Net income | $ | 11 | $ | 5,879 | $ | 6,084 | $ | 10,848 | ||||
Net income per share, basic | $ | 0.00 | $ | 0.88 | $ | 0.88 | $ | 1.62 | ||||
Weighted average number of shares used in computing basic net | 6,944,664 | 6,707,341 | 6,918,709 | 6,704,306 | ||||||||
Net income per share, diluted | $ | 0.00 | $ | 0.75 | $ | 0.78 | $ | 1.38 | ||||
Weighted average number of shares used in computing diluted | 7,795,149 | 7,867,001 | 7,789,101 | 7,887,584 | ||||||||
Semler Scientific, Inc. | ||||||
Condensed Balance Sheets | ||||||
(In thousands of U.S. Dollars, except share and per share data) | ||||||
June 30, | December 31, | |||||
2024 | 2023 | |||||
Unaudited | ||||||
Assets | ||||||
Current Assets: | ||||||
Cash and cash equivalents | $ | 7,332 | $ | 57,200 | ||
Restricted cash | 132 | 132 | ||||
Trade accounts receivable, net of allowance for credit losses of $243 and $287, respectively | 7,470 | 6,125 | ||||
Short-term notes held for investments | 6,100 | — | ||||
Inventory, net | 385 | 445 | ||||
Prepaid expenses and other current assets | 2,271 | 2,042 | ||||
Total current assets | 23,690 | 65,944 | ||||
Assets for lease, net | 1,768 | 2,285 | ||||
Property and equipment, net | 620 | 720 | ||||
Long-term investments | 512 | 512 | ||||
Notes held for investment | — | 5,372 | ||||
Intangible digital assets | 54,945 | — | ||||
Other non-current assets | 127 | 270 | ||||
Deferred tax assets, net of valuation allowance of $1,207 and $0, respectively | 3,124 | 2,962 | ||||
Total assets | $ | 84,786 | $ | 78,065 | ||
Liabilities and Stockholders' Equity | ||||||
Current liabilities: | ||||||
Accounts payable | $ | 227 | $ | 402 | ||
Accrued expenses | 5,086 | 4,502 | ||||
Deferred revenue | 840 | 1,120 | ||||
Other short-term liabilities | 211 | 176 | ||||
Total current liabilities | 6,364 | 6,200 | ||||
Long-term liabilities: | ||||||
Other long-term liabilities | 24 | 70 | ||||
Total long-term liabilities | 24 | 70 | ||||
Commitments and contingencies (Note 15) | ||||||
Stockholders' equity: | ||||||
Common stock, $0.001 par value; 50,000,000 shares authorized; 7,202,146 and 7,099,441 shares | 7 | 7 | ||||
Additional paid-in capital | 12,504 | 11,985 | ||||
Retained earnings | 65,887 | 59,803 | ||||
Total stockholders' equity | 78,398 | 71,795 | ||||
Total liabilities and stockholders' equity | $ | 84,786 | $ | 78,065 | ||
Semler Scientific, Inc. | ||||||
Condensed Statements of Cash Flows | ||||||
Unaudited | ||||||
(In thousands of U.S. Dollars) | ||||||
Six months ended June 30, | ||||||
2024 | 2023 | |||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net income | $ | 6,084 | $ | 10,848 | ||
Reconciliation of Net Income to Net Cash Provided by Operating Activities: | ||||||
Depreciation | 346 | 279 | ||||
Deferred tax expense | (163) | (207) | ||||
Loss on disposal of assets for lease | 319 | 114 | ||||
Gain on short-term investments | — | (237) | ||||
Allowance for credit losses | (44) | 92 | ||||
Change in fair value of notes held for investment | (128) | 217 | ||||
Change in fair value of digital assets | 5,055 | — | ||||
Stock-based compensation | 295 | 860 | ||||
Changes in Operating Assets and Liabilities: | ||||||
Trade accounts receivable | (1,292) | (2,240) | ||||
Inventory | 60 | (7) | ||||
Prepaid expenses and other current assets | (135) | (950) | ||||
Other non-current assets | 43 | 106 | ||||
Accounts payable | (175) | (326) | ||||
Accrued expenses | 584 | 3,495 | ||||
Other current and non-current liabilities | (291) | 13 | ||||
Net Cash Provided by Operating Activities | 10,558 | 12,057 | ||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Additions to property and equipment | (48) | (260) | ||||
Purchase of notes held for investment | (500) | (500) | ||||
Purchase of digital assets | (60,000) | — | ||||
Proceeds from maturities of short-term investments | — | 57,707 | ||||
Purchase of short-term investments | — | (49,728) | ||||
Purchase of assets for lease | (674) | |||||
Net Cash (Used in) Provided by Investing Activities | (60,548) | 6,545 | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Repurchase of warrants | — | (1,949) | ||||
Taxes paid related to net settlement of equity awards | (45) | (172) | ||||
Stock issuance expenses | (102) | — | ||||
Proceeds from exercise of stock options | 269 | — | ||||
Net Cash Provided by (Used in) Financing Activities | 122 | (2,121) | ||||
(DECREASE) INCREASE IN CASH | (49,868) | 16,481 | ||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD | 57,332 | 23,014 | ||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD | $ | 7,464 | $ | 39,495 | ||
Semler Scientific, Inc. | |||||||||||||||
Digital Assets- Additional Information | |||||||||||||||
Rollforward of bitcoin holdings | |||||||||||||||
Unaudited | |||||||||||||||
Source of | Digital Assets | Change in | Digital Assets | Approximate | Approximate | ||||||||||
Balance as of March 31, 2024 | $ | — | $ | — | $ | — | — | $ | — | ||||||
Digital assets purchased | (a) | 60,000 | — | 60,000 | 877 | 68,436 | |||||||||
Change in fair value of the digital assets | — | (5,055) | (5,055) | — | — | ||||||||||
Balance as of June 30, 2024 | $ | 60,000 | $ | (5,055) | $ | 54,945 | 877 | $ | 68,436 | ||||||
(a) | Cash from operations |
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and Semler Scientific is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). Semler Scientific also invests in bitcoin and has adopted bitcoin as its primary treasury asset. Additional information about Semler Scientific can be found at www.semlerscientific.com.
Forward-Looking Statements
This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "believe," "goal," "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding expansion of the healthcare business; seeking a new 510(k) clearance for QuantaFlo with expanded indications for use; purchase of additional bitcoin; value of bitcoin and ability to execute on the bitcoin treasury strategy; among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such as such as risks inherent with investing in bitcoin, including bitcoin's volatility; risk of implementing a new bitcoin treasury strategy; risk that insurance plans and other customers will not continue to license its cardiovascular testing products; risk of changes in the reimbursement landscape for its customers including related to the Centers for Medicare and Medicaid Services (CMS) rate announcement; risk of obtaining a new 510(k) clearance for expanded indications; along with those other risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.
No Offer or Solicitation
This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any securities of Semler Scientific, Inc., nor shall there be any offer, solicitation or sale of such securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
INVESTOR CONTACT:
Renae Cormier
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$25.42 |
| Daily Change: | -0.50 -1.93 |
| Daily Volume: | 82,489 |
| Market Cap: | US$181.240M |
August 31, 2023 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
